表紙
市場調查報告書

分子診斷相關的事業合作:條件與契約內容 (2014∼2020年)

Global Molecular Diagnostics Partnering Terms and Agreements 2014 to 2020

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 939920
出版日期 內容資訊 英文 450+ Pages
商品交期: 最快1-2個工作天內
價格
分子診斷相關的事業合作:條件與契約內容 (2014∼2020年) Global Molecular Diagnostics Partnering Terms and Agreements 2014 to 2020
出版日期: 2020年06月01日內容資訊: 英文 450+ Pages
簡介

本報告提供分子診斷用的醫藥品開發相關近來 (2014∼2020年)的聯盟交易的趨勢相關分析,整體交易形成數量的變化,及財務方面 (付款條件) 的趨勢,主要企業 (共25家公司) 的交易形成的動向,契約條件的趨勢,各技術、各產品的趨勢等調查,近幾年主要的聯盟交易 (共7,650件)等詳細資訊彙整,為您概述為以下內容。

目錄

摘要整理

第1章 簡介

第2章 分子診斷相關的交易形成的趨勢

  • 簡介
  • 分子診斷相關的交易形成:近幾年趨勢
  • 分子診斷相關的交易形成:各交易類型
  • 分子診斷相關的交易形成:各業界
  • 分子診斷相關的交易形成:各開發階段
  • 分子診斷相關的交易形成:各技術種類
  • 分子診斷相關的交易形成:各適應症
  • 分子診斷相關的事業合作:交易條件
    • 交易總額
    • 預付款金
    • 階段性付款
    • 權利金費率

第3章 分子診斷相關的代表性交易

  • 簡介
  • 分子診斷相關的合作最活躍的企業

第4章 分子診斷相關的合作最活躍的企業

  • 簡介
  • 在分子診斷的領域最活躍的企業:交易總額
  • 主要企業的簡介

第5章 分子診斷的契約文件名錄

  • 簡介
  • 分子診斷相關的資本交易趨勢:可閱覽契約文章的交易情況

第6章 分子診斷相關的交易形成:各技術種類

第7章 事業合作的資源中心

  • 線上合作
  • 合作活動
  • 參考文件:交易形成趨勢的相關

附錄

  • 附錄 (1):分子診斷相關的聯盟交易一覽,各企業名 (ABC順序,2014∼2020年)
  • 附錄 (2):分子診斷相關的聯盟交易一覽,各開發階段 (2014∼2020年)
  • 附錄 (3):分子診斷相關的聯盟交易一覽,各交易類型 (2014∼2020年)
  • 附錄 (4):分子診斷相關的聯盟交易一覽,各治療領域 (2014∼2020年)
  • 附錄 (5):交易的種類定義
目錄
Product Code: CP2102mol

‘The Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report’ provides comprehensive understanding and unprecedented access to the molecular diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

‘The Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report’ provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.

The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over7650 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Molecular Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Molecular Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Molecular Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Molecular Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Molecular Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Molecular Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Molecular Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Molecular Diagnostics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Molecular Diagnostics technologies and products.

Key benefits

‘Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020’ provides the reader with the following key benefits:

  • In-depth understanding of Molecular Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Molecular Diagnostics dealmakers since 2014
  • Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Molecular Diagnostics Partnering Terms and Areements 2014-2020’ is intended to provide the reader with an in-depth understanding and access to Molecular Diagnostics trends and structure of deals entered into by leading companies worldwide.

‘Global Molecular Diagnostics Partnering Terms and Agreements’ includes:

  • Trends in Molecular Diagnostics dealmaking in the biopharma industry since 2014
  • Analysis of Molecular Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Molecular Diagnostics deals
  • Access to Molecular Diagnostics contract documents
  • Leading Molecular Diagnostics deals by value since 2014
  • Most active Molecular Diagnostics dealmakers since 2014

In ‘Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

‘The Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts report’ provides comprehensive access to available deals and contract documents for over 700 Molecular Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report’ provides the reader with the following key benefits:

  • In-depth understanding of Molecular Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Molecular Diagnostics dealmakers since 2014
  • Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Molecular Diagnostics dealmaking

  • 2.1. Introduction
  • 2.2. Molecular Diagnostics partnering over the years
  • 2.3. Most active Molecular Diagnostics dealmakers
  • 2.4. Molecular Diagnostics partnering by deal type
  • 2.5. Molecular Diagnostics partnering by therapy area
  • 2.6. Deal terms for Molecular Diagnostics partnering
    • 2.6.1 Molecular Diagnostics partnering headline values
    • 2.6.2 Molecular Diagnostics deal upfront payments
    • 2.6.3 Molecular Diagnostics deal milestone payments
    • 2.6.4 Molecular Diagnostics royalty rates

Chapter 3 - Leading Molecular Diagnostics deals

  • 3.1. Introduction
  • 3.2. Top Molecular Diagnostics deals by value

Chapter 4 - Most active Molecular Diagnostics dealmakers

  • 4.1. Introduction
  • 4.2. Most active Molecular Diagnostics dealmakers
  • 4.3. Most active Molecular Diagnostics partnering company profiles

Chapter 5 - Molecular Diagnostics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Molecular Diagnostics contracts dealmaking directory

Chapter 6 - Molecular Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Molecular Diagnostics deals by company A-Z
  • Appendix 2 - Molecular Diagnostics deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - Molecular Diagnostics deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty
  • Appendix 4 - Molecular Diagnostics deals by therapy area
  • Appendix 5 -Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Molecular Diagnostics partnering since 2014
  • Figure 2: Active Molecular Diagnostics dealmaking activity
  • Figure 3: Molecular Diagnostics partnering by deal type since 2014
  • Figure 4: Molecular Diagnostics partnering by disease type since 2014
  • Figure 5: Molecular Diagnostics deals with a headline value
  • Figure 6: Molecular Diagnostics deals with an upfront value
  • Figure 7: Molecular Diagnostics deals with a milestone value
  • Figure 8: Molecular Diagnostics deals with a royalty rate value
  • Figure 9: Top Molecular Diagnostics deals by value since 2014
  • Figure 10: Most active Molecular Diagnostics dealmakers 2014 to 2019
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events